Drug Profile
Research programme: antibody-drug conjugates - ImmunoGen
Alternative Names: Anti-c-Met-DGN 549; Anti-c-Met-DM4; anti-CD123 ADC - Immunogen; Anti-CD33-3m; Anti-CD56-3m; Anti-cMet antibody-drug conjugate; Anti-EGFR-3m; Anti-FRα-3m; CD19-targeting antibody-drug conjugate; huB4-DGN462; hucMet-DM4; hucMet27-DGN 549; IGN P1; IGNs-ADCs; M-DGN549; M9346A NL DMLatest Information Update: 14 Feb 2024
Price :
$50
*
At a glance
- Originator ImmunoGen
- Class Antineoplastics; Immunoconjugates; Maytansinoids
- Mechanism of Action Alkylating agents; DNA cross linking agents; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 28 Dec 2022 Preclinical development is ongoing USA (Immunogen pipeline, December 2022)
- 28 Dec 2022 Preclinical trials in Solid tumours in USA (Parenteral) (Immunogen pipeline, December 2022)